Belgium 2019 Belgium Grant Winner

Given the strong scientific preclinical and clinical data indicating the potential of microbiota-altering therapies for PD are promising, and the anecdotal (case study) evidence that FMT works for these patients, there is an urgent need to reliably test this potential therapy in a randomized clinical trial.

Our study will be the first worldwide to investigate the potential therapeutic effect of FMT on symptoms and disease progression in patients with PD in a double-blind, placebo-controlled randomized clinical trial (source: clinicaltrials.gov).